DeepMed Research

European Organisation For Research & Treatment Of Cancer

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.eortc.be

Clinical Trials

Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate

Phase 3

Terminated

Conditions: Gastrointestinal Stromal Tumor

Interventions: Procedure: therapeutic conventional surgery
Drug: imatinib mesylate

First Posted Date: 2009-08-11

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 12

Registration Number: NCT00956072

Locations: 🇮🇹
European Organization for Research and Treatment of Cancer, Naples, Italy

Sunitinib Malate in Treating Patients With Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

First Posted Date: 2009-08-06

Last Posted Date: 2018-07-26

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 9

Registration Number: NCT00953459

Locations: 🇳🇱
Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands

Post-operative or Early Salvage XRT and ADT for High Risk PCa

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Radiation: 3-dimensional conformal radiation therapy
Drug: antiandrogen therapy
Drug: leuprolide acetate

First Posted Date: 2009-07-31

Last Posted Date: 2014-07-04

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 87

Registration Number: NCT00949962

Locations: 🇫🇷
European Organization for Research and Treatment of Cancer, Grenoble, France

Radiation Therapy With or Without Goserelin and Cyproterone in Treating Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

First Posted Date: 2009-02-23

Last Posted Date: 2012-07-11

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Registration Number: NCT00849082

Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia

Phase 1

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Drug: clofarabine
Drug: cytarabine
Drug: idarubicin

First Posted Date: 2009-02-06

Last Posted Date: 2012-07-20

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 114

Registration Number: NCT00838240

Locations: 🇧🇪
Institut Jules Bordet, Brussel, Belgium
🇮🇹
Azienda Ospedallera Universitaria - Policlinico Tor Vergata, Roma, Italy
🇮🇹
Univesita Degli Studi "La Sapienza", Roma, Italy

and more 7 locations

Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: capecitabine
Drug: oxaliplatin

First Posted Date: 2008-10-03

Last Posted Date: 2016-10-12

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 1094

Registration Number: NCT00766155

Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor

Phase 3

Conditions: Gastrointestinal Stromal Tumor

Interventions: Drug: imatinib mesylate

First Posted Date: 2008-05-28

Last Posted Date: 2014-07-04

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 946

Registration Number: NCT00685828

Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery

Phase 2

Terminated

Conditions: Head and Neck Cancer

First Posted Date: 2008-03-28

Last Posted Date: 2018-07-09

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 47

Registration Number: NCT00646659

Locations: 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium

Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma

Phase 2

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2008-02-29

Last Posted Date: 2021-02-03

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 78

Registration Number: NCT00626730

Locations: 🇨🇭
Hopital Cantonal Universitaire de Geneve, Geneva, Switzerland

Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

Phase 3

Active, not recruiting

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: temozolomide
Genetic: DNA methylation analysis
Other: laboratory biomarker analysis
Radiation: radiation therapy
Procedure: quality-of-life assessment
Procedure: adjuvant therapy

First Posted Date: 2008-02-29

Last Posted Date: 2023-09-11

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 751

Registration Number: NCT00626990

Locations: 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachussets General Hospital Cancer Center, Boston, Massachusetts, United States

and more 129 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy